
One-Shot Gene Therapies & Peptides | Longevity News Roundup—Week 31, 2026
Notes de l’épisode
Hosts:
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: https://qrco.de/bgXpKn
----------
Sponsor: FlexBeam
FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.
Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.
Link: rechargehealthas.sjv.io/jRQyQ5
----------
In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine new Alzheimer's therapies, the growing debate around experimental peptides, expanding access to investigational treatments, rapid advances in metabolic disease and encouraging progress in longevity gene therapy.
- Voyager Therapeutics reported that its investigational gene therapy VY1706 reduced tau protein by up to 75% in non-human primates for six months after a single intravenous dose, using a novel blood-brain barrier delivery approach.
- An advisory panel to the US Food and Drug Administration recommended broader access to compounded wellness peptides despite concerns over limited human evidence, highlighting the growing tension between consumer demand, regulatory oversight and the need for robust clinical trials.
- Vandria announced that its oral mitochondrial therapy VNA-318 safely reached the brain in its first human study, supporting once-daily dosing ahead of planned Alzheimer's trials.
- Montana advanced Right to Try legislation that could expand patient access to investigational therapies beyond traditional approval pathways, raising new questions about evidence, transparency and responsible implementation.
- D&D Pharmatech reported that its once-weekly dual GLP-1/glucagon receptor agonist zabopegdutide rapidly reduced liver fat and stiffness, with benefits seen even among participants who experienced minimal weight loss.
- Genflow Biosciences reported positive early results from its SIRT6 gene therapy trial in aging dogs, supporting the growing use of companion animals as a bridge toward future human longevity therapies
----------
News & References:
- Voyager’s single-dose gene therapy cuts tau by 75% → https://longevity.technology/news/voyagers-single-dose-gene-therapy-cuts-tau-by-75/
- FDA panel backs peptides over its own scientists → https://longevity.technology/news/fda-panel-backs-peptides-over-its-own-scientists/
- Vandria’s experimental Alzheimer’s pill proves safe, reaches target in first human study → https://longevity.technology/news/vandrias-experimental-alzheimers-pill-proves-safe-reaches-target-in-first-human-study/
- Montana takes next step on experimental therapies → https://longevity.technology/news/montana-takes-next-step-on-experimental-therapies/
- Zabopegdutide shows rapid, weight-independent liver benefits in Phase 2 → https://longevity.technology/news/zabopegdutide-shows-rapid-weight-independent-liver-benefits-in-phase-2/
- Genflow reports positive early results in aging-dog gene therapy trial → https://longevity.technology/news/genflow-reports-positive-early-results-in-aging-dog-gene-therapy-trial/